PRAGUE, Czech Republic, April 18, 2012 (GLOBE NEWSWIRE) -- Today researchers will report initial findings of a post-FDA-approval study using Left Ventricular Assist Devices as destination therapy for heart failure patients. The findings show signs that destination therapy may soon be a permanent treatment option for patients as an alternative to transplantation.
